Targeted Therapy Market - 2024-2033
The Targeted Therapy Market was valued at US$ 79.18 billion in 2024 and is anticipated to reach US$ 147.16 billion by 2033, at a CAGR of 0.072 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Targeted Therapy Market.
This report delivers a comprehensive overview of the Targeted Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Targeted Therapy Market. The Targeted Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Targeted Therapy Market Scope:
Major Highlights
This report delivers a comprehensive overview of the Targeted Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Targeted Therapy Market. The Targeted Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Targeted Therapy Market.
This report delivers a comprehensive overview of the Targeted Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Targeted Therapy Market. The Targeted Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
Targeted Therapy Market Scope:
Major Highlights
This report delivers a comprehensive overview of the Targeted Therapy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Targeted Therapy Market. The Targeted Therapy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Indication
4.2. Snippet by Route of Administration
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Incidence and Prevalence of Cancer
7. RISING NOVEL TARGETED THERAPY APPROVALS
8. RESTRAINTS
8.1. High Cost of Targeted Therapies
9. PATIENT ADHERENCE AND COMPLIANCE ISSUES
10. OPPORTUNITIES
10.1. Expansion of Therapeutic Applications
10.1.1. Impact Analysis
11. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
11.1. Market Leaders and Pioneers
11.2. Latest Developments and Breakthroughs
11.3. Pipeline Analysis
11.4. Regulatory and Reimbursement Landscape
11.5. Pricing Analysis
11.6. Porter’s Five Forces Analysis
11.7. Patent Analysis
11.8. SWOT Analysis
11.9. Unmet Needs and Gaps
11.10. Recommended Strategies for Market Entry and Expansion
11.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
12. GLOBAL TARGETED THERAPY MARKET, BY TYPE
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.1.2. Market Attractiveness Index, By Type
12.2. Monoclonal Antibodies
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. VEGF Inhibitors
12.2.4. Antibody Drug Conjugates
12.2.5. CD Antigen-Targeted mAbs
12.2.6. EGFR Inhibitors
12.2.7. HER2 Inhibitors
12.2.8. Others
12.3. Small Molecules
12.3.1. PARP Inhibitors
12.3.2. Tyrosine Kinase Inhibitors
12.3.3. BRAF/MEK inhibitors
12.3.4. CDK Inhibitors
12.3.5. Others
13. GLOBAL TARGETED THERAPY MARKET, BY INDICATION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.1.2. Market Attractiveness Index, By Indication
13.2. Leukemia
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Breast Cancer
13.4. Lung Cancer
13.5. GI Cancers
13.6. Melanoma
13.7. Others
14. GLOBAL TARGETED THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.1.2. Market Attractiveness Index, By Route of Administration
14.2. Oral
14.2.1. Introduction
14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
14.3. Parenteral
15. GLOBAL TARGETED THERAPY MARKET, BY REGION
15.1. Introduction
15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
15.1.2. Market Attractiveness Index, By Region
15.2. North America
15.2.1. Introduction
15.2.2. Key Region-Specific Dynamics
15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.2.6.1. U.S.
15.2.6.2. Canada
15.2.6.3. Mexico
15.3. Europe
15.3.1. Introduction
15.3.2. Key Region-Specific Dynamics
15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.3.6.1. Germany
15.3.6.2. U.K.
15.3.6.3. France
15.3.6.4. Spain
15.3.6.5. Italy
15.3.6.6. Rest of Europe
15.4. South America
15.4.1. Introduction
15.4.2. Key Region-Specific Dynamics
15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.4.6.1. Brazil
15.4.6.2. Argentina
15.4.6.3. Rest of South America
15.5. Asia-Pacific
15.5.1. Introduction
15.5.2. Key Region-Specific Dynamics
15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.5.6.1. China
15.5.6.2. India
15.5.6.3. Japan
15.5.6.4. South Korea
15.5.6.5. Rest of Asia-Pacific
15.6. Middle East and Africa
15.6.1. Introduction
15.6.2. Key Region-Specific Dynamics
15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
16. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
16.1. Competitive Overview and Key Market Players
16.2. Market Share Analysis and Positioning Matrix
16.3. Strategic Partnerships, Mergers & Acquisitions
16.4. Key Developments in Product Portfolios and Innovations
16.5. Company Benchmarking
17. COMPANY PROFILES
Key Market Players
1. F. HOFFMANN-LA ROCHE LTD
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Novartis AG
1.3. Pfizer Inc.
1.4. AstraZeneca.
1.5. Eisai Inc.
1.6. Johnson & Johnson Services, Inc.
1.7. Bristol-Myers Squibb Company.
1.8. Incyte.
1.9. Eli Lilly and Company
1.10. Exelixis, Inc.
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY TYPE
4.1. Snippet by Indication
4.2. Snippet by Route of Administration
5. SNIPPET BY REGION
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. Rising Incidence and Prevalence of Cancer
7. RISING NOVEL TARGETED THERAPY APPROVALS
8. RESTRAINTS
8.1. High Cost of Targeted Therapies
9. PATIENT ADHERENCE AND COMPLIANCE ISSUES
10. OPPORTUNITIES
10.1. Expansion of Therapeutic Applications
10.1.1. Impact Analysis
11. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
11.1. Market Leaders and Pioneers
11.2. Latest Developments and Breakthroughs
11.3. Pipeline Analysis
11.4. Regulatory and Reimbursement Landscape
11.5. Pricing Analysis
11.6. Porter’s Five Forces Analysis
11.7. Patent Analysis
11.8. SWOT Analysis
11.9. Unmet Needs and Gaps
11.10. Recommended Strategies for Market Entry and Expansion
11.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
12. GLOBAL TARGETED THERAPY MARKET, BY TYPE
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.1.2. Market Attractiveness Index, By Type
12.2. Monoclonal Antibodies
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.2.3. VEGF Inhibitors
12.2.4. Antibody Drug Conjugates
12.2.5. CD Antigen-Targeted mAbs
12.2.6. EGFR Inhibitors
12.2.7. HER2 Inhibitors
12.2.8. Others
12.3. Small Molecules
12.3.1. PARP Inhibitors
12.3.2. Tyrosine Kinase Inhibitors
12.3.3. BRAF/MEK inhibitors
12.3.4. CDK Inhibitors
12.3.5. Others
13. GLOBAL TARGETED THERAPY MARKET, BY INDICATION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
13.1.2. Market Attractiveness Index, By Indication
13.2. Leukemia
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Breast Cancer
13.4. Lung Cancer
13.5. GI Cancers
13.6. Melanoma
13.7. Others
14. GLOBAL TARGETED THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.1.2. Market Attractiveness Index, By Route of Administration
14.2. Oral
14.2.1. Introduction
14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
14.3. Parenteral
15. GLOBAL TARGETED THERAPY MARKET, BY REGION
15.1. Introduction
15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
15.1.2. Market Attractiveness Index, By Region
15.2. North America
15.2.1. Introduction
15.2.2. Key Region-Specific Dynamics
15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.2.6.1. U.S.
15.2.6.2. Canada
15.2.6.3. Mexico
15.3. Europe
15.3.1. Introduction
15.3.2. Key Region-Specific Dynamics
15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.3.6.1. Germany
15.3.6.2. U.K.
15.3.6.3. France
15.3.6.4. Spain
15.3.6.5. Italy
15.3.6.6. Rest of Europe
15.4. South America
15.4.1. Introduction
15.4.2. Key Region-Specific Dynamics
15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.4.6.1. Brazil
15.4.6.2. Argentina
15.4.6.3. Rest of South America
15.5. Asia-Pacific
15.5.1. Introduction
15.5.2. Key Region-Specific Dynamics
15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
15.5.6.1. China
15.5.6.2. India
15.5.6.3. Japan
15.5.6.4. South Korea
15.5.6.5. Rest of Asia-Pacific
15.6. Middle East and Africa
15.6.1. Introduction
15.6.2. Key Region-Specific Dynamics
15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
16. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
16.1. Competitive Overview and Key Market Players
16.2. Market Share Analysis and Positioning Matrix
16.3. Strategic Partnerships, Mergers & Acquisitions
16.4. Key Developments in Product Portfolios and Innovations
16.5. Company Benchmarking
17. COMPANY PROFILES
Key Market Players
1. F. HOFFMANN-LA ROCHE LTD
1.1. Company Overview
1.1.1. Product Portfolio
1.1.1.1. Product Description
1.1.1.2. Product Key Performance Indicators (KPIs)
1.1.1.3. Historic and Forecasted Product Sales
1.1.1.4. Product Sales Volume
1.1.2. Financial Overview
1.1.2.1. Company Revenue’s
1.1.2.2. Geographical Revenue Shares
1.1.2.3. Revenue Forecasts
1.1.3. Key Developments
1.1.3.1. Mergers & Acquisitions
1.1.3.2. Key Product Development Activities
1.1.3.3. Regulatory Approvals, etc.
1.1.4. SWOT Analysis
1.2. Novartis AG
1.3. Pfizer Inc.
1.4. AstraZeneca.
1.5. Eisai Inc.
1.6. Johnson & Johnson Services, Inc.
1.7. Bristol-Myers Squibb Company.
1.8. Incyte.
1.9. Eli Lilly and Company
1.10. Exelixis, Inc.
2. APPENDIX
2.1. About Us and Services
2.2. Contact Us
